These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34001002)

  • 1. Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine.
    Nahas SJ; Hindiyeh N; Friedman DI; Elbuluk N; Kellerman DJ; Foreman PK; Schmidt P
    J Headache Pain; 2021 May; 22(1):37. PubMed ID: 34001002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta™) for the acute treatment of migraine.
    Rapoport AM; Ameri M; Lewis H; Kellerman DJ
    Pain Manag; 2020 Nov; 10(6):359-366. PubMed ID: 32752932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
    Spierings EL; Brandes JL; Kudrow DB; Weintraub J; Schmidt PC; Kellerman DJ; Tepper SJ
    Cephalalgia; 2018 Feb; 38(2):215-224. PubMed ID: 29022755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
    Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
    Tepper SJ; Dodick DW; Schmidt PC; Kellerman DJ
    Headache; 2019 Apr; 59(4):509-517. PubMed ID: 30698272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
    Tuchman M; Hee A; Emeribe U; Silberstein S
    CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
    Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
    Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.
    Dodick DW; Tepper SJ; Friedman DI; Gelfand AA; Kellerman DJ; Schmidt PC
    Headache; 2018 Jul; 58(7):986-992. PubMed ID: 29782049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
    Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
    CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial.
    Loder E; Freitag FG; Adelman J; Pearlmand S; Abu-Shakra S
    Curr Med Res Opin; 2005 Mar; 21(3):381-9. PubMed ID: 15811207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study.
    Loder E; Silberstein SD; Abu-Shakra S; Mueller L; Smith T
    Headache; 2004 Feb; 44(2):120-30. PubMed ID: 14756849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
    Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
    Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).
    Winner P; Farkas V; Štillová H; Woodruff B; Liss C; Lillieborg S; Raines S;
    Headache; 2016 Jul; 56(7):1107-19. PubMed ID: 27329280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.
    Geraud G; Compagnon A; Rossi A;
    Eur Neurol; 2002; 47(2):88-98. PubMed ID: 11844897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zolmitriptan: a review of its use in migraine.
    Spencer CM; Gunasekara NS; Hills C
    Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
    Gawel M; Aschoff J; May A; Charlesworth BR;
    Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
    Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
    Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.